{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:52Z","timestamp":1792800892591,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>atezolizumab\u2013bevacizumab is the standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but potentially life-threatening immune-related adverse event. Evidence regarding ICI rechallenge after myocarditis remains limited, particularly in patients with HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 59-year-old man with hepatitis C\u2013related cirrhosis and advanced HCC with portal vein tumor thrombosis, treated with atezolizumab-bevacizumab. After two treatment cycles, he developed non-fulminant ICI-associated myocarditis, characterized by chest pain, elevated cardiac biomarkers, and cardiac magnetic resonance imaging findings consistent with acute myocarditis. Atezolizumab was discontinued, and high-dose corticosteroid therapy was initiated, resulting in complete clinical, biochemical, and radiological recovery. The patient initially achieved a partial tumor response with normalization of alpha-fetoprotein (AFP). During temporary treatment interruption, he subsequently developed radiological disease progression, including enlargement of the hepatic lesion, portal vein tumor thrombosis, and extensive supra- and infradiaphragmatic necrotic lymphadenopathy. Following multidisciplinary evaluation and documented resolution of myocarditis, atezolizumab\u2013bevacizumab rechallenge was undertaken under corticosteroid cover. The patient received six additional cycles with good tolerance, no recurrence of myocarditis, and stable disease on follow-up imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that atezolizumab\u2013bevacizumab rechallenge may be feasible in carefully selected patients with advanced HCC after recovery from non-fulminant ICI-associated myocarditis under close multidisciplinary supervision. It also highlights the importance of histological confirmation in atypical nodal progression during immunotherapy, particularly when imaging findings may be confounded by alternative explanations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1931800","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:30:31Z","timestamp":1789014631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Atezolizumab-bevacizumab rechallenge after immune checkpoint inhibitor-associated myocarditis in advanced hepatocellular carcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Myriam","family":"Ayari","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Internal Security Forces Hospital La Marsa","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarra Ben","family":"Azouz","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Internal Security Forces Hospital La Marsa","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Ncir","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Internal Security Forces Hospital La Marsa","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Bouyahia","sequence":"additional","affiliation":[{"name":"Radiology Department, Internal Security Forces Hospital La Marsa","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarra Ben","family":"Rejeb","sequence":"additional","affiliation":[{"name":"Pathology Department, Internal Security Forces Hospital La Marsa","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Charfi","sequence":"additional","affiliation":[{"name":"Radiology Department, Internal Security Forces Hospital La Marsa","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taieb","family":"Jomni","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Internal Security Forces Hospital La Marsa","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01442-2","article-title":"A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma","volume":"14","author":"Iwasaki","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.02.004","article-title":"Rechallenge after severe immune checkpoint inhibitor myocarditis","volume":"7","author":"Bailly","year":"2025","journal-title":"JACC CardioOncology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2024.10.027","article-title":"Unusual location of metastatic lymph nodes of hepatocellular carcinoma in the mediastinum: Case report","volume":"20","author":"El Ouardi","year":"2025","journal-title":"Radiol Case Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.12.001","article-title":"Management of immune checkpoint inhibitor\u2013induced myocarditis","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC CardioOncology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247737","article-title":"Immune checkpoint inhibitors-associated myocarditis: diagnosis, treatment and current status on rechallenge","volume":"12","author":"Frascaro","year":"2023","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.125.077976","article-title":"Restarting immune checkpoint inhibitors after ICI myocarditis: a prospective cohort","volume":"153","author":"Jebnoun","year":"2026","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.04.037","article-title":"Immune checkpoint inhibitor rechallenge in a patient with previous fulminant myocarditis","volume":"199","author":"Menachery","year":"2023","journal-title":"Am J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59111946","article-title":"Tolerated re-challenge of immunotherapy in a patient with ICI associated myocarditis: A case report and literature review","volume":"59","author":"Shalata","year":"2023","journal-title":"Med (Mex)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.70024","article-title":"Rechallenge of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma","volume":"55","author":"Suzuki","year":"2025","journal-title":"Hepatol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i3.414","article-title":"Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma","volume":"13","author":"Uka","year":"2007","journal-title":"World J Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000529201","article-title":"Efficacy of local treatment in lymph node metastasis from hepatocellular carcinoma","volume":"12","author":"Lee","year":"2023","journal-title":"Liver Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1148\/radiology.216.3.r00se24698","article-title":"Extrahepatic metastases of hepatocellular carcinoma","volume":"216","author":"Katyal","year":"2000","journal-title":"Radiology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001620","article-title":"A rare case of hepatocellular carcinoma presenting as cervical lymph node metastases and review of the literature","volume":"12","author":"Tkachuk","year":"2025","journal-title":"ACG Case Rep J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/23247096211058489","article-title":"A case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"9","author":"Watanabe","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01761-6","article-title":"A case of hepatocellular carcinoma with \u201cpseudoprogression\u201d followed by complete response to atezolizumab plus bevacizumab","volume":"16","author":"Odagiri","year":"2023","journal-title":"Clin J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4710-24","article-title":"Hepatocellular carcinoma presenting with pseudoprogression in a patient receiving atezolizumab plus bevacizumab combination therapy","volume":"64","author":"Osuga","year":"2025","journal-title":"Intern Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1931800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:30:42Z","timestamp":1789014642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1931800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1931800"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1931800","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1931800"}}